ALACRIS CMTA
LIVE

Serial Number

98027963

Owner

Alacris Theranostics GmbH

Attorney

Kimberly Miller

Filing Date

Jun 5, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ALACRIS CMTA Trademark

Serial Number: 98027963

ALACRIS CMTA is a trademark filed by Alacris Theranostics GmbH on June 5, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Alacris Theranostics GmbH (2 trademarks)

Max-Planck-Str. 3
Berlin 12489 , DE

Entity Type: 99

Trademark Details

Filing Date

June 5, 2023

Registration Date

Not Registered

Published for Opposition

July 9, 2024

Goods & Services

Analysis of human tissues for medical research; Research laboratory services in the field of cancer diagnostics; Scientific research for medical purposes in the area of cancerous diseases; Medical research laboratory services; Scientific investigations for medical purposes; Providing scientific information in the field of medical disorders and their treatment

Advisory services relating to medical problems; Advisory services relating to medical services; Medical analysis of human serum for medical treatment purposes provided by medical laboratories; Medical analysis of human tissues for medical treatment purposes provided by medical laboratories; Breast cancer screening services; Bowel cancer screening services; Cervical cancer screening services; Collection and preservation of human blood; Compilation of medical reports, namely, providing medical information to patients in the form of reports in the field of molecular tumor analysis; Conducting of medical examinations; Health clinic services, namely medical; Genetic testing for medical purposes; DNA screening for medical purposes; Immunodetection services for medical purposes; Lung cancer screening services; Medical analysis services for cancer diagnosis and prognosis; Medical analysis services for the diagnosis of cancer; Medical analysis for the diagnosis and treatment of persons; Medical care and analysis services relating to patient treatment; Medical counseling; Medical diagnostic services; Medical screening; Medical services in the field of oncology; Medical services for the treatment of skin cancer; Medical services for the diagnosis of conditions of the human body; Medical laboratory services for the analysis of samples taken from patients for diagnostic and treatment purposes; Medical laboratory services for the analysis of blood samples taken from patients for diagnostic and treatment purposes; Medical testing for diagnostic or treatment purposes; Medical testing services relating to the diagnosis and treatment of disease; Providing cancer screening services; Prostate cancer screening services; Preparation of reports providing medical information to patients relating to medical matters in the field of cancer diagnosis; Public health counseling; Provision of medical services; RNA or DNA analysis for cancer diagnosis and prognosis; Services for the testing of blood for diagnostic and treatment purposes provided by medical laboratories; Services for the testing of sera for diagnostic and treatment purposes provided by medical laboratories; Services for the testing of urine for diagnostic and treatment purposes provided by medical laboratories; Testicular cancer screening services; Next generation sequencing of tumor and control samples for diagnostic and treatment purposes provided by medical laboratories; Bioinformatic analysis of next generation sequencing data for pan-cancer diagnostics, provided by medical laboratories

Diagnostic preparations and substances for medical purposes; Biological reagents for medical use; Chemical preparations for testing blood for medical purposes; Chemical preparations for use in DNA analysis, namely medical; Chemical reagents for medical use; Chemical test reagents, namely medical; Clinical diagnostic reagents for medical purposes; Clinical medical reagents; Diagnostic agents for medical use; Diagnostic agents for pharmaceutical use; Diagnostic biomarker reagents for medical purposes; Diagnostic chemical reagents for medical use; Diagnostic preparations for medical purposes; Diagnostic reagents for medical use; Diagnostic substances for medical use; Diagnostic testing materials for medical use, namely, medical diagnostic test media for gene sequencing of tumor samples, medical diagnostic test media for gene sequencing of blood samples, and medical diagnostic test media for gene sequencing of tissue samples; Immunoassay reagents for medical use; In vitro diagnostic preparations for medical use; Biological indicators for medical diagnosis; Medical diagnostic reagents and assays for testing of body fluids; Preparations for detecting genetic predispositions for medical purposes; preparations consisting of pre-mixed reactants for medical diagnosis; Reagents for analytical purposes, namely for medical purposes; Reagents for blood grouping, namely for medical purposes; Reagents for in-vitro laboratory use, namely for medical purposes; Reagents for use in analysis, namely for medical purposes; Reagents for use with analyzers, namely for medical purposes; Reagents for use in diagnostic tests, namely for medical purposes

Filing History

TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 16, 2026 TROA
WITHDRAWAL OF ATTORNEY GRANTED
Jun 30, 2026 WOAG
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Jun 30, 2026 WOAR
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 2, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 2, 2026 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 2, 2026 GNRN
NON-FINAL ACTION E-MAILED
Mar 2, 2026 GNRT
SU - NON-FINAL ACTION - WRITTEN
Mar 2, 2026 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Feb 27, 2026 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 26, 2026 AITU
USE AMENDMENT FILED
Aug 21, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Aug 21, 2025 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 26, 2025 EXRA
SOU EXTENSION 1 GRANTED
Feb 25, 2025 EX1G
SOU EXTENSION 1 FILED
Feb 25, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 25, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 3, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 9, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jul 9, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 19, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 30, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 29, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 29, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 29, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 5, 2024 GNRN
NON-FINAL ACTION E-MAILED
Mar 5, 2024 GNRT
NON-FINAL ACTION WRITTEN
Mar 5, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 26, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 9, 2023 NWOS
NEW APPLICATION ENTERED
Jun 8, 2023 NWAP